☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
alexion
Alexion’s Ultomiris (ravulizumab) Receives the Health Canada’s Approval for Generalized Myasthenia Gravis
January 18, 2023
Alexion to Acquire LogicBio Therapeutics for ~$68M
October 3, 2022
PharmaShots Weekly Snapshots (August 30 - September 03, 2021)
September 3, 2021
PharmaShots Weekly Snapshots (August 23, 27, 2021)
August 27, 2021
Alexion to Discontinue its P-III CHAMPION-ALS Trial of Ultomiris (ravulizumab) for Amyotrophic Lateral Sclerosis
August 23, 2021
PharmaShots Weekly Snapshots (July 26 - 30, 2021)
July 30, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.